Monitor the RSNA 2026 presentation on December 3, 2026 for initial clinical performance data, which will be the first catalyst for this initiative. Also watch for updates on the STRATIFY study and any future FDA or Medicare milestones.
Price Chart
Executive Summary
Biodesix announced a Digital Diagnostics initiative to build a multimodal lung diagnostic platform combining blood-based biomarkers, imaging biomarkers, and AI, starting with a radiomics-based lung nodule risk assessment test developed with Vanderbilt University. The first product is expected to be commercially available in 2028, with initial data to be presented at RSNA on December 3, 2026. This is a strategic expansion of the company's lung diagnostics franchise into imaging, but the initiative is early-stage with no near-term revenue impact.
Key Facts
- Biodesix announced a Digital Diagnostics initiative to create a multimodal diagnostic platform combining blood-based biomarkers, imaging biomarkers, and AI.
- First product is a radiomics-based lung nodule risk assessment test developed with Vanderbilt University and Vanderbilt Health.
- Initial performance data will be presented at RSNA 2026 Annual Meeting on December 3, 2026.
- Commercial availability is anticipated in 2028.
- Biodesix has received IRB approval for STRATIFY (NCT07858552), a prospective clinical study expected to commence in Q4 2026.
- Biodesix has engaged with the FDA and Medicare to support regulatory and reimbursement pathways.
- Biodesix has established an Independent Diagnostic Testing Facility (IDTF) for operational scale.
Financial Impact
No financial terms, deal value, or revenue projections were disclosed. The initiative is early-stage with commercial availability not expected until 2028.
Risk Factors
- Commercial availability not expected until 2028 — no near-term revenue contribution.
- Clinical validation and regulatory clearance are still pending; the test may not achieve expected performance or reimbursement.
- Multimodal platform is early-stage and may face technical, competitive, or adoption challenges.
- The company's forward-looking statements are subject to risks including tariffs, capital availability, and business strategy execution.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3383136 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | Press Release | $23.87 | awaiting T+20 | — | $21.26 (−10.93%) |
Oct 19, 2026 8d ago | Press Release | $23.40 | awaiting T+20 | — | $21.26 (−9.15%) |
Aug 15, 2026 10w ago | Institutional Cluster | $23.25 $27.70 | ▲ +19.14% | ▲ +21.12% | $21.26 (−8.56%) |
Aug 13, 2026 10w ago | Insider Buy | $24.00 $27.40 | ▲ +14.17% | ▲ +16.16% | $21.26 (−11.42%) |
Aug 12, 2026 10w ago | Insider Buy | $23.79 $26.97 | ▲ +13.35% | ▲ +15.09% | $21.26 (−10.63%) |
Aug 5, 2026 11w ago | 8-K | $22.10 $26.48 | ▲ +19.80% | ▲ +19.20% | $21.26 (−3.80%) |
Jun 1, 2026 21w ago | EFFECT | $15.27 $22.55 | ▲ +47.68% | ▲ +48.97% | $21.26 (+39.23%) |
May 4, 2026 25w ago | Press Release | $14.94 $15.44 | ▲ +3.35% | ▼ −1.61% | $21.26 (+42.30%) |
Apr 20, 2026 27w ago | Press Release | $13.17 $14.25 | ▲ +8.20% | ▲ +4.00% | $21.26 (+61.43%) |
Mar 20, 2026 31w ago | Press Release | $14.88 $13.17 | ▼ −11.46% | ▼ −20.78% | $21.26 (+42.92%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers